Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665738 · ClinicalTrials.gov registry record · NA
Two-fraction HDR Monotherapy for Localized Prostate Cancer
A NA study of Prostate Adenocarcinoma and Localized Prostate Carcinoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT05665738: Recruiting NA study of Prostate Adenocarcinoma and Localized Prostate Carcinoma, sponsored by University of California, San Francisco.
NCT05665738 is a NA study of Prostate Adenocarcinoma and Localized Prostate Carcinoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 17 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05665738, a NA study of Prostate Adenocarcinoma and Localized Prostate Carcinoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fractions on separate days, or at least 6 hours apart. Clinically, this regimen, if shown to be safe and effective in future studies, has the potential to reduce operative resources and logistical stresses on brachytherapy departments.
Primary Outcome
The proportion of participants with reported grade 3 or higher genitourinary (GU) or gastrointestinal (GI) toxicities, as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be reported.
Conditions Studied
Interventions
- RADIATION High Dose Rate Monotherapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2029-02-28 |
| Phase | NA |
What NCT05665738 shows while recruiting
NCT05665738 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which High Dose Rate Monotherapy is the first listed.
NCT05665738 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05665738 about?
NCT05665738 is a clinical study titled "Two-fraction HDR Monotherapy for Localized Prostate Cancer". This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fract...
What is the current status of trial NCT05665738?
This trial is currently recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2024-09-11. Estimated completion is 2029-02-28.
What conditions does trial NCT05665738 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma.
What interventions are being tested in trial NCT05665738?
The interventions under investigation include: High Dose Rate Monotherapy (RADIATION).
Who is sponsoring clinical trial NCT05665738?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05665738 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05665738's enrollment target sits among peer trials
17 90th of 99 higher than 10 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
RECRUITING · NA
-
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
RECRUITING · NA
-
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
-
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI